Mortality Outcome of Controlled Blood Pressure Participants

Mortality Outcome of Controlled Hypertension in Randomized Controlled or Open-label Study Intentionally Directed Intervention Effect Blood Pressure: A Systematic Review and Meta-Analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07067632

Acronym

HTN-Mort

Enrollment

100

Registered

2025-07-16

Start date

2025-07-01

Completion date

2027-02-01

Last updated

2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension (HTN), Valid MeSH Conditions

Keywords

hypertension, cardiovascular death

Brief summary

Despite advances in antihypertensive therapy, some patients with well-controlled blood pressure still experience fatal outcomes. This paradox raises critical questions about the efficacy of blood pressure-targeted interventions and whether BP control alone ensures survival. This systematic review and meta-analysis aims to evaluate all-cause mortality and cardiovascular death among hypertensive patients who achieved BP targets in RCTs or open-label trials. To determine whether achieving controlled blood pressure through intentional intervention (pharmacological or procedural) in RCTs or open-label studies reduces mortality (all-cause and cardiovascular) in hypertensive patients.

Detailed description

Sensitivity Analyses Excluding high-risk of bias studies Excluding short follow-up (\<1 year)

Interventions

DRUGAntihypertensive treatment

Any intervention (pharmacological, device-based, lifestyle) intentionally directed at lowering BP Control groups receiving placebo, standard of care, or no intervention

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults ≥18 years with diagnosed hypertension Blood pressure controlled at target values defined by the study (e.g., \<140/90 mmHg or \<130/80 mmHg) Any comorbidity allowed unless the study focuses on pregnancy or pediatric population

Exclusion criteria

* Observational or retrospective studies Pediatric or pregnant participants Case reports, editorials, or conference abstracts without full data Studies not reporting mortality outcomes separately for controlled BP

Design outcomes

Primary

Measure	Time frame	Description
All-cause mortality	100 year	All cause mortality by controlable hypertension treatment

Countries

Thailand

Contacts

PRINCIPAL_INVESTIGATORNathaphong Dejthida, MD

DejthidaNathaphong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026